In ALL, IKZF1 alterations are found in 10–80%, depending on ALL subtype and patient age [22–29], however, studies in AML are scarce and report much lower frequencies ranging from 1.3–2.6% [36, 37], which is comparable to the 2.8% of patients harboring IKZF1 alterations in our cohort. This evidence concerns the gene IKZF1 and acute myeloid leukemia.